Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature
Journal of Pediatric Gastroenterology and Nutrition · 2024-08 · 79 (2) · 229-237
DOI: 10.1002/jpn3.12230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024-05. Verfasst von Ning Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Terminology as Topic, Liver Cirrhosis, Nutrition Surveys, Elasticity Imaging Techniques. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIOSH CDC HHS, Prevent Cancer Foundation, NIDDK NIH HHS.
Abstract (Originalsprache)
Objective
To apply the new nomenclature for steatotic liver diseases (SLD), replacing nonalcoholic fatty liver disease (NAFLD) with metabolic dysfunction‐associated steatotic liver disease (MASLD), in adolescents using National Health and Nutrition Examination Survey (NHANES) data.
Methods
Among 1410 adolescents (12–19 years) in NHANES (2017‐March, 2020), the controlled attenuation parameter (CAP) of transient elastography (TE) was used to define steatosis and fibrosis (TE ≥ 7.4 kPa). Obesity and alanine aminotransferase (ALT) ≥ 80 U/L were used to identify adolescents qualifying for hepatology referral according to practice guidelines. NAFLD was defined as liver steatosis without a specific exposure; it has no cardiometabolic risk factor requirement, unlike MASLD.
Results
Steatosis (yes/no) is the first decision point in the new diagnostic protocol; however, criteria for steatosis are undefined. At the supplier (EchoSens)‐recommended CAP threshold of 240 dB/m, 30.5% (95% confidence interval [CI]: 27.1%–34.0%) of adolescents had SLD and about 85% of adolescents with NAFLD met criteria for MASLD. The other 15% would receive an ambiguous diagnosis of either cryptogenic SLD or possible MASLD. At higher CAP thresholds, MASLD/NAFLD concordance increased and approached 100%. Among adolescents with MASLD‐fibrosis, only 8.8% (95% CI: 0%–19.3%) had overweight/obese and ALT ≥ 80 U/L.
Conclusions
The new nomenclature highlights the high prevalence of liver steatosis. At the CAP threshold of 240 dB/m, however, approximately 15% of adolescents would receive an ambiguous diagnosis, which could lead to confusion and worry. Fewer than 10% of adolescents with MASLD‐fibrosis had overweight/obese and ALT ≥ 80 U/L. Revised guidelines are needed to ensure that the other 90% receive appropriate referral and liver disease care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Ning Ma
Förderung
- NIOSH CDC HHS
- Prevent Cancer Foundation
- NIDDK NIH HHS
Zitieren
APA
Ma, N., Bansal, M., Chu, J., & Branch, A. D. (2024). Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature. Journal of Pediatric Gastroenterology and Nutrition, 79(2), 229-237. https://doi.org/10.1002/jpn3.12230
Vancouver
Ma N, Bansal M, Chu J, Branch AD. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature. Journal of Pediatric Gastroenterology and Nutrition. 2024;79(2):229-237. doi:10.1002/jpn3.12230
BibTeX
@article{Ma2024,
author = {Ma, Ning and Bansal, Meena and Chu, Jaime and Branch, Andrea D},
title = {Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {79},
number = {2},
pages = {229--237},
doi = {10.1002/jpn3.12230}
}
EUVIMED